Clinical trial

A Study to Evaluate the Effect of Umeclidinium (UMEC) as Combination Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02257372

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention UMEC DPI Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo DPI Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention ICS/LABA medication Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Albuterol/salbutamol Metered Dose Inhaler (MDI) Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Study to Evaluate the Effect of Umeclidinium (UMEC) as Combination Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2014-09-30

PhasePHASE4

Conditions

Pulmonary Disease, Chronic Obstructiveunresolved

Interventions

UMEC DPIDRUG

Placebo DPIDRUG

ICS/LABA medicationDRUG

Albuterol/salbutamol Metered Dose Inhaler (MDI)DRUG

Sponsors & collaborators

GlaxoSmithKlinelead sponsor

Mapped research locations

BerlinGermany3 ThessalonikiGreece2 AthensGreece1 OlomoucCzechia1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02257372 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.